-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Initiates Coverage On Zevra Therapeutics with Buy Rating, Announces Price Target of $23

Benzinga·03/16/2026 10:45:39
Listen to the news
BTIG analyst Kambiz Yazdi initiates coverage on Zevra Therapeutics (NASDAQ:ZVRA) with a Buy rating and announces Price Target of $23.